NEW ORLEANS--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported updated results based on a planned median three-year follow up of patients from the large, international Phase III VISTA1 trial. These data were presented at the 51st Annual Meeting of the American Society of Hematology (ASH), held December 5-8, 2009 in New Orleans, Louisiana. These data were the basis for a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) earlier this year. The FDA has granted priority review status to that application.
